Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

26.04 -2.54

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.03

Massimo

27.12

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+51.09% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

826M

2.9B

Apertura precedente

28.58

Chiusura precedente

26.04

Notizie sul Sentiment di mercato

By Acuity

50%

50%

145 / 340 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 ago 2026, 23:56 UTC

Correlated Moves
News

Royal Gold shares are higher in after-market trading following CEO Bill Heissenbuttel's upcoming presentation at the Jefferies Global Industrials Conference on September 10.

27 ago 2026, 23:56 UTC

Correlated Moves
News

Diamondback Energy has risen in after-market hours following its joint venture for the Solitude Pipeline System, with analysts estimating a fair value of $232.17.

27 ago 2026, 23:51 UTC

News

Carlyle Group reported second-quarter revenue exceeding analyst expectations. In after-market trading, shares are advancing, reflecting a solid performance backdrop.

27 ago 2026, 23:51 UTC

Correlated Moves
News

The USD/HUF is trading higher, reflecting gains since Wednesday. A decline in initial jobless claims suggests strength in the U.S. economy.

27 ago 2026, 23:31 UTC

News

NAPCO Security Technologies Inc shares are lower in after-market hours, following broader market declines despite a 10% revenue increase in the fiscal fourth quarter.

27 ago 2026, 23:26 UTC

News

Vanguard Mortgage-Backed Securities ETF is trading lower in after-market hours, amid a decline in the US 10Y Treasury Bond Index and investor sentiment shifts.

27 ago 2026, 23:11 UTC

News

Shares of Regenxbio are higher in after-market trading following a $949.4K insider purchase by director Gregor Ciongoli of 102.6K shares.

27 ago 2026, 23:06 UTC

Social Media
News

BioNTech SE's COVID-19 vaccine COMIRNATY® XFG receives FDA approval for adults 65 and older. Shares are trading higher in after-market hours.

27 ago 2026, 23:06 UTC

News

Shoals Technologies Group Inc shares declined in after-market trading despite winning a patent case against Voltage, LLC, with a jury awarding over $96 million.

27 ago 2026, 23:02 UTC

News

Permian Resources Corp shares are higher in after-market hours, boosted by Citigroup's outlook on the Permian Basin becoming the top U.S. natural gas producer.

27 ago 2026, 23:02 UTC

News

PDD Holdings reported second-quarter revenue of RMB112.4 billion, missing estimates. Shares are roughly flat in after-market trading amid rising operating expenses.

27 ago 2026, 23:02 UTC

Correlated Moves
News

Coinbase Global Inc. announced a token-backed mortgage product with Better Mortgage, boosting shares modestly higher in after-market trading.

27 ago 2026, 23:02 UTC

Social Media
News

Salesforce Inc. remains roughly flat in after-market hours amid discussions on short-selling dynamics and positive user experiences with its CRM system.

27 ago 2026, 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

27 ago 2026, 23:02 UTC

News

Main Street Capital plans a supplemental dividend for December 2026, continuing its $0.30-per-share quarterly distribution. Shares are trading higher in after-market hours.

27 ago 2026, 23:02 UTC

Social Media
News

CrowdStrike Holdings Inc shares are lower in after-market hours, reflecting broader market declines despite recent strong earnings and positive revenue outlook.

27 ago 2026, 23:02 UTC

News

SFL Corporation reported Q2 revenue of $200.77 million and net income of $33.79 million. Shares are higher in after-market trading following the announcement.

27 ago 2026, 23:02 UTC

Social Media
Event
News

Gap Inc. shares rise in after-market trading following Q2 earnings that beat EPS estimates and included an adjusted EPS guidance increase.

27 ago 2026, 23:02 UTC

Social Media
News

Ulta Beauty Inc. shares are lower in after-market trading despite reporting strong second-quarter earnings and raising fiscal year guidance for net sales growth.

27 ago 2026, 23:02 UTC

News

Constellation Brands names Alex Alvarez as chief supply chain officer for its beer division. Shares are higher in after-market trading following initial dips.

27 ago 2026, 23:02 UTC

News

Rivian Automotive shares fell in after-market trading after CFO Claire McDonough announced her departure for GE Vernova, effective October 30.

27 ago 2026, 23:02 UTC

Event
Social Media
News

Affirm Holdings shares rise in after-market hours following a record fiscal fourth-quarter profit and revenue of $1.17 billion, exceeding estimates.

27 ago 2026, 23:02 UTC

Social Media
News

Pfizer and BioNTech received FDA approval for their XFG-adapted COVID-19 vaccine, COMIRNATY XFG, boosting shares in after-market trading.

27 ago 2026, 23:02 UTC

Social Media
News

Marvell Technology reported Q2 revenue of $2.74 billion, exceeding estimates, but shares are trading lower in after-market hours following the results.

27 ago 2026, 23:02 UTC

News
Correlated Moves

USD/PLN is gaining modestly today, influenced by initial jobless claims falling to 203,000, indicating ongoing strength in the labor market.

27 ago 2026, 23:02 UTC

Correlated Moves
Social Media
News

NVIDIA pauses revenue-sharing deals with AI cloud firms amid antitrust concerns, contributing to a modest decline in shares during after-market hours.

27 ago 2026, 23:02 UTC

Social Media
News

Veeva Systems Inc shares are lower in after-market trading, reflecting a broader market downturn despite earlier gains. The stock remains strong relative to its 20-day moving average.

27 ago 2026, 23:02 UTC

News

Bilibili Inc shares declined during after-market hours despite reporting strong growth in daily active users and advertising revenue. The stock remains below its 20-day moving average.

27 ago 2026, 23:01 UTC

News

Otis Worldwide Corp shares are lower in after-market trading, despite securing a significant contract for modernization at Tianjin 117 Tower in China.

27 ago 2026, 23:01 UTC

News
Correlated Moves

Intuit Inc. shares are lower in after-market trading following a downgrade by BofA Securities, which cut its fiscal 2027 revenue estimate to $23.4 billion.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

51.09% in crescita

Previsioni per 12 mesi

Media 39.33 USD  51.09%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

145 / 340 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat